residue on acyl carrier protein (ACP), which is responsible for shuttling around 4`-PP. This pathway is essential for the functioning of the Fatty Acid Synthase (FAS) enzyme and allows LS9 a certain degree of monopoly in fatty acid generation from microorganisms since it has patented such an integral component. Legal Implications Another intriguing aspect of this patent is that for LS9 to employ it, they cannot continue using FAS proteins which have been patented by other companies. Therefore, LS9 must be careful in how they implement this patent. Thus far, no conflict-of-interest claims have been filed against this patent. Overview of Patent Specifications The initial patent application contained 43 components which LS9 endeavoured to have covered under this patent. Of these 43 components, 5 are protected under this patent. These include the use of a protein with 80% homology to PPTase for the purposes of generation of fatty acids or aldehydes, culturing a cell expressing such a PPTase under conditions permissive for production of fatty acids or aldehydes, overexpressing PPTase in growth medium selective for fatty acid production, and also delineates a means of overcoming iron-induced inhibition of PPTase. These specifications address pretreatment conditions detailing decreasing iron-inhibition present in the microbes used for this research (See Above). Submission Submitted in 2011, this patent was published under the USPA, under application number 20130035513 on February 7, 2013 under the title of Methods and Compositions for Enhanced Production of Fatty Aldehydes and Fatty Alcohols. Gene Cassette and Culture Medium for Commercial Purposes This patent builds upon several other patents filed by LS9 and forms a gene cassette plasmid which has the potential to be taken up by target microorganism and used to generate fatty acids. One of the main components of this patent is that the target microorganism will use the fermentation of carbohydrates for a direct route for the production of fatty esters without producing undesired side-products like glycerin characteristic of conventional fatty ester production. To achieve this, the pathway and enzymes have been engineered from pCLTFW.atfA1, pLoxPcat2, pCLTFWcat, R6K1, and POpAm. These were not the intellectual property of the LS9 before this point. However, after acceptance of this patent, the combination of these plasmids, the final product has achieved a distinction significant enough to warrant the allowance of a patent to this process. Legal Implications There does not exist any legal implications implicit in the application. The assortment of genes